grant
Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach
Organization MASSACHUSETTS GENERAL HOSPITALLocation BOSTON, UNITED STATESPosted 1 Jul 2023Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY2025Acetic AcidsAdoptedAfrica South of the SaharaAlgorithmsAnisotropyAssayAutomobile DrivingBenchmarkingBest Practice AnalysisBioassayBioinformaticsBiological AssayBiomedical EngineeringBudgetsCDK4ICDKN2CDKN2 GenesCDKN2ACDKN2A geneCMM2CRISPRCRISPR/Cas systemCancersCause of DeathCervicalCervical CancerCervical Cancer ScreeningCervix CancerCessation of lifeClinicalClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsComplementComplement ProteinsCountryCyclin-Dependent Kinase Inhibitor 2A GeneCytologyCytology and PathologyCytopathologyDNADNA MarkersDNA biomarkersDeathDecentralizationDeoxyribonucleic AcidDetectionDeveloped CountriesDiagnosticDiseaseDisorderEarly identificationEligibilityEligibility DeterminationEquipmentFeedbackFluorescence AnisotropyFruitGeneral HospitalsGenesGhanaGold CoastGuidelinesGynecologic OncologyHPVHPV detectionHPV infectionHPV screeningHPV testingHPV-High RiskHigh Risk Oncogenic HPVHigh risk HPVHigh risk Human PapillomavirusHigh risk Human papilloma virusHumanHuman Papilloma VirusHuman Papilloma Virus detectionHuman Papilloma Virus screeningHuman PapillomavirusHuman ResourcesHuman papilloma virus infectionHuman papillomavirus infectionINK4INK4AIncidenceIndustrialized CountriesIndustrialized NationsInfectious Human Wart VirusInternationalInterventionLMICLaboratoriesLow-resource areaLow-resource communityLow-resource environmentLow-resource regionLow-resource settingMTS1MTS1 GenesMachine LearningMalignant Cervical NeoplasmMalignant Cervical TumorMalignant Neoplasm of the CervixMalignant NeoplasmsMalignant TumorMalignant Tumor of the CervixMalignant Tumor of the Cervix UteriMalignant Uterine Cervix NeoplasmMalignant Uterine Cervix TumorMalignant neoplasm of cervix uteriManpowerMassachusettsMeasurementMessenger RNAModern ManMotionNobel PrizeNon-Polyadenylated RNANucleic AcidsOncogenicOpticsPap TestPap screeningPap smearPapanicolaou SmearPapanicolaou TestPathologyPerformancePositionPositioning AttributeProtocol ScreeningProviderPublic HealthRNARNA Gene ProductsRNA markerReporterResearch ResourcesResearch SpecimenResource-constrained areaResource-constrained communityResource-constrained environmentResource-constrained regionResource-constrained settingResource-limited areaResource-limited communityResource-limited environmentResource-limited regionResource-limited settingResource-poor areaResource-poor communityResource-poor environmentResource-poor regionResource-poor settingResourcesRibonucleic AcidRiskSamplingScienceSiteSpecificitySpecimenSub-Saharan AfricaSubsaharan AfricaSystemTP16TSG9ATechnical ExpertiseTechnologyTemperatureTestingTimeTractionTriageUP2UPIIUPK2UPK2 geneUgandaUniversitiesUroplakin 2Uterine Cervix CancerViralVisualWomanWomen's mortalitybenchmarkbio-engineeredbio-engineersbioengineeringbiological engineeringcancer invasivenesscervical cancer early detectioncervical screeningclinical diagnosticscomplementationcostdeath among femalesdeath among womendeath in femalesdeath in womendeath rate among womendeath rate in womendetection methoddetection proceduredetection techniquedeveloped countrydeveloped nationdeveloped nationsdietary fruitdrivingempowermentexpectationfemale deathfemale mortalityglobal healthhigh riskhrHPVhuman papillomavirus based testinghuman papillomavirus testinginnovateinnovationinnovativeinterestiterative designlow and middle-income countriesmRNAmachine based learningmalignancymedical diagnosticmembermortality among femalesmortality among womenmortality in femalesmortality in womenmulti-modalitymultidisciplinarymultimodalityneoplasm/cancernewsnovelnucleic acid detectionoperationoperationsopticalover-treatmentovertreatmentp14ARFp16 Genesp16INK4 Genesp16INK4A Genesp16INK4apandemicpandemic diseasepersonnelpilot testpoint of careportabilityprecancer cervical detectionresponsescreeningscreeningstechnical skillsuroplakin IIuser-friendlywart viruswomen's deathwomen's death rate
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
ABSTRACT
Challenges. Despite being curable when caught early, cervical cancer remains the second leading cause of
death in women living in sub-Saharan Africa. Even with available screening technologies (cytology, visual
inspection with acetic acid (VIA), and sometimes high-risk Human Papillomavirus [hrHPV] testing), only
10-20% of eligible women…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click